Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype
Identifieur interne : 004848 ( PascalFrancis/Corpus ); précédent : 004847; suivant : 004849Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype
Auteurs : Sunil R. Lakhani ; Jorge S. Reis-Filho ; Laura Fulford ; Frederique Penault-Llorca ; Marc Van Dervijver ; Suzanne Parry ; Timothy Bishop ; Javier Benitez ; Carmen Rivas ; Yves-Jean Bignon ; Jenny Chang-Claude ; Ute Hamann ; Cees J. Cornelisse ; Peter Devilee ; Matthias W. Beckmann ; Carolin Nestle-Kr Mling ; Peter A. Daly ; Neva Haites ; Jenny Varley ; Fiona Lalloo ; Gareth Evans ; Christine Maugard ; Hanne Meijers-Heijboer ; Jan G. M. Klijn ; Edith Olah ; Barry A. Gusterson ; Silvana Pilotti ; Paolo Radice ; Siegfried Scherneck ; Hagay Sobol ; Jocelyne Jacquemier ; Teresa Wagner ; Julian Peto ; Michael R. Stratton ; Lesley Mcguffog ; Douglas F. EastonSource :
- Clinical cancer research [ 1078-0432 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose:To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus, 12%; CK5/6: 58% versus 7%; CK17: 53%versus10%; osteonectin: 43%versus19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 05-0335175 INIST |
|---|---|
| ET : | Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype |
| AU : | LAKHANI (Sunil R.); REIS-FILHO (Jorge S.); FULFORD (Laura); PENAULT-LLORCA (Frederique); VAN DERVIJVER (Marc); PARRY (Suzanne); BISHOP (Timothy); BENITEZ (Javier); RIVAS (Carmen); BIGNON (Yves-Jean); CHANG-CLAUDE (Jenny); HAMANN (Ute); CORNELISSE (Cees J.); DEVILEE (Peter); BECKMANN (Matthias W.); NESTLE-KRÄMLING (Carolin); DALY (Peter A.); HAITES (Neva); VARLEY (Jenny); LALLOO (Fiona); EVANS (Gareth); MAUGARD (Christine); MEIJERS-HEIJBOER (Hanne); KLIJN (Jan G. M.); OLAH (Edith); GUSTERSON (Barry A.); PILOTTI (Silvana); RADICE (Paolo); SCHERNECK (Siegfried); SOBOL (Hagay); JACQUEMIER (Jocelyne); WAGNER (Teresa); PETO (Julian); STRATTON (Michael R.); MCGUFFOG (Lesley); EASTON (Douglas F.) |
| AF : | The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 6 aut.); Molecular and Cellular Pathology, University of Queensland/Brisbane/Australie (1 aut.); Centre Jean Perrin/Clermont-Ferrand/France (4 aut., 10 aut.); The Netherlands Cancer Institute/Amsterdam/Pays-Bas (5 aut.); Imperial Cancer Research Fund Genetic Epidemiology Laboratory, St. James University Hospital/Leeds/Royaume-Uni (7 aut.); Department of Genetics, Dpto Genetica Humana. Centro Nacional nvestigaciones Oncológicas/Madrid/Espagne (8 aut.); Department of Pathology, Fundación Jiménez Díaz, Autonomous University of Madrid/Madrid/Espagne (9 aut.); Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis/Heidelberg/Allemagne (11 aut., 12 aut.); Department of Genetics and Pathology, Leiden University/Leiden/Pays-Bas (13 aut., 14 aut.); Departments of Obstetrics and Gynecology, Friedrich Alexander University/Erlangen/Allemagne (15 aut., 16 aut.); Department of Medicine, Trinity College Medical School, St James Hospital/Dublin/Irlande (17 aut.); Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen/Aberdeen/Royaume-Uni (18 aut.); CRUK Cancer Genetics Group, Paterson Institute for Cancer Research/Manchester/Royaume-Uni (19 aut.); Department of Medical Genetics, St. Mary's Hospital/Manchester/Royaume-Uni (20 aut., 21 aut.); University Hospital/Nantes/France (22 aut.); Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam/Rotterdam/Pays-Bas (23 aut., 24 aut.); Department of Molecular Biology, National Institute of Oncology/Budapest/Hongrie (25 aut.); Department of Pathology, Western Infirmary, University of Glasgow/Scotland/Royaume-Uni (26 aut.); Department of Pathology, Istituto Nazionale Tumori/Milan/Italie (27 aut.); Department of Experimental Oncology, Istituto Nazionale Tumori/Milan/Italie (28 aut.); Max-Delbruck-Centrum fur Moleculare Medizin, Tumorgenetik/Berlin/Allemagne (29 aut.); Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute/Marseille/France (30 aut., 31 aut.); Department of Obstetrics and Gynaecology, General Hospital, University of Vienna/Autriche (32 aut.); Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories/Royaume-Uni (33 aut., 34 aut.); London School of Hygiene and Tropical Medicine/London/Royaume-Uni (33 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Clinical cancer research; ISSN 1078-0432; Etats-Unis; Da. 2005; Vol. 11; No. 14; Pp. 5175-5180; Bibl. 28 ref. |
| LA : | Anglais |
| EA : | Purpose:To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus, 12%; CK5/6: 58% versus 7%; CK17: 53%versus10%; osteonectin: 43%versus19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients. |
| CC : | 002B02R |
| FD : | Prédiction; Facteur prédictif; Gène suppresseur tumeur; Gène BRCA1; Homme; Glande mammaire pathologie; Tumeur maligne; Récepteur biologique; Phénotype; Cancer sein |
| ED : | Prediction; Predictive factor; Tumor suppressor gene; BRCA1 gene; Human; Mammary gland diseases; Malignant tumor; Biological receptor; Phenotype; Breast cancer |
| SD : | Predicción; Factor predictivo; Gen supresor tumor; Gen BRCA1; Hombre; Glándula mamaria patología; Tumor maligno; Receptor biológico; Fenotipo; Cáncer del pecho |
| LO : | INIST-26073.354000137962310150 |
| ID : | 05-0335175 |
Links to Exploration step
Pascal:05-0335175Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype</title><author><name sortKey="Lakhani, Sunil R" sort="Lakhani, Sunil R" uniqKey="Lakhani S" first="Sunil R." last="Lakhani">Sunil R. Lakhani</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Molecular and Cellular Pathology, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Reis Filho, Jorge S" sort="Reis Filho, Jorge S" uniqKey="Reis Filho J" first="Jorge S." last="Reis-Filho">Jorge S. Reis-Filho</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fulford, Laura" sort="Fulford, Laura" uniqKey="Fulford L" first="Laura" last="Fulford">Laura Fulford</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation><inist:fA14 i1="03"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Van Dervijver, Marc" sort="Van Dervijver, Marc" uniqKey="Van Dervijver M" first="Marc" last="Van Dervijver">Marc Van Dervijver</name><affiliation><inist:fA14 i1="04"><s1>The Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Parry, Suzanne" sort="Parry, Suzanne" uniqKey="Parry S" first="Suzanne" last="Parry">Suzanne Parry</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bishop, Timothy" sort="Bishop, Timothy" uniqKey="Bishop T" first="Timothy" last="Bishop">Timothy Bishop</name><affiliation><inist:fA14 i1="05"><s1>Imperial Cancer Research Fund Genetic Epidemiology Laboratory, St. James University Hospital</s1><s2>Leeds</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Benitez, Javier" sort="Benitez, Javier" uniqKey="Benitez J" first="Javier" last="Benitez">Javier Benitez</name><affiliation><inist:fA14 i1="06"><s1>Department of Genetics, Dpto Genetica Humana. Centro Nacional nvestigaciones Oncológicas</s1><s2>Madrid</s2><s3>ESP</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rivas, Carmen" sort="Rivas, Carmen" uniqKey="Rivas C" first="Carmen" last="Rivas">Carmen Rivas</name><affiliation><inist:fA14 i1="07"><s1>Department of Pathology, Fundación Jiménez Díaz, Autonomous University of Madrid</s1><s2>Madrid</s2><s3>ESP</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bignon, Yves Jean" sort="Bignon, Yves Jean" uniqKey="Bignon Y" first="Yves-Jean" last="Bignon">Yves-Jean Bignon</name><affiliation><inist:fA14 i1="03"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chang Claude, Jenny" sort="Chang Claude, Jenny" uniqKey="Chang Claude J" first="Jenny" last="Chang-Claude">Jenny Chang-Claude</name><affiliation><inist:fA14 i1="08"><s1>Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hamann, Ute" sort="Hamann, Ute" uniqKey="Hamann U" first="Ute" last="Hamann">Ute Hamann</name><affiliation><inist:fA14 i1="08"><s1>Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cornelisse, Cees J" sort="Cornelisse, Cees J" uniqKey="Cornelisse C" first="Cees J." last="Cornelisse">Cees J. Cornelisse</name><affiliation><inist:fA14 i1="09"><s1>Department of Genetics and Pathology, Leiden University</s1><s2>Leiden</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Devilee, Peter" sort="Devilee, Peter" uniqKey="Devilee P" first="Peter" last="Devilee">Peter Devilee</name><affiliation><inist:fA14 i1="09"><s1>Department of Genetics and Pathology, Leiden University</s1><s2>Leiden</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Beckmann, Matthias W" sort="Beckmann, Matthias W" uniqKey="Beckmann M" first="Matthias W." last="Beckmann">Matthias W. Beckmann</name><affiliation><inist:fA14 i1="10"><s1>Departments of Obstetrics and Gynecology, Friedrich Alexander University</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Nestle Kr Mling, Carolin" sort="Nestle Kr Mling, Carolin" uniqKey="Nestle Kr Mling C" first="Carolin" last="Nestle-Kr Mling">Carolin Nestle-Kr Mling</name><affiliation><inist:fA14 i1="10"><s1>Departments of Obstetrics and Gynecology, Friedrich Alexander University</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Daly, Peter A" sort="Daly, Peter A" uniqKey="Daly P" first="Peter A." last="Daly">Peter A. Daly</name><affiliation><inist:fA14 i1="11"><s1>Department of Medicine, Trinity College Medical School, St James Hospital</s1><s2>Dublin</s2><s3>IRL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Haites, Neva" sort="Haites, Neva" uniqKey="Haites N" first="Neva" last="Haites">Neva Haites</name><affiliation><inist:fA14 i1="12"><s1>Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen</s1><s2>Aberdeen</s2><s3>GBR</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Varley, Jenny" sort="Varley, Jenny" uniqKey="Varley J" first="Jenny" last="Varley">Jenny Varley</name><affiliation><inist:fA14 i1="13"><s1>CRUK Cancer Genetics Group, Paterson Institute for Cancer Research</s1><s2>Manchester</s2><s3>GBR</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lalloo, Fiona" sort="Lalloo, Fiona" uniqKey="Lalloo F" first="Fiona" last="Lalloo">Fiona Lalloo</name><affiliation><inist:fA14 i1="14"><s1>Department of Medical Genetics, St. Mary's Hospital</s1><s2>Manchester</s2><s3>GBR</s3><sZ>20 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Evans, Gareth" sort="Evans, Gareth" uniqKey="Evans G" first="Gareth" last="Evans">Gareth Evans</name><affiliation><inist:fA14 i1="14"><s1>Department of Medical Genetics, St. Mary's Hospital</s1><s2>Manchester</s2><s3>GBR</s3><sZ>20 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Maugard, Christine" sort="Maugard, Christine" uniqKey="Maugard C" first="Christine" last="Maugard">Christine Maugard</name><affiliation><inist:fA14 i1="15"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Meijers Heijboer, Hanne" sort="Meijers Heijboer, Hanne" uniqKey="Meijers Heijboer H" first="Hanne" last="Meijers-Heijboer">Hanne Meijers-Heijboer</name><affiliation><inist:fA14 i1="16"><s1>Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>23 aut.</sZ><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Klijn, Jan G M" sort="Klijn, Jan G M" uniqKey="Klijn J" first="Jan G. M." last="Klijn">Jan G. M. Klijn</name><affiliation><inist:fA14 i1="16"><s1>Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>23 aut.</sZ><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Olah, Edith" sort="Olah, Edith" uniqKey="Olah E" first="Edith" last="Olah">Edith Olah</name><affiliation><inist:fA14 i1="17"><s1>Department of Molecular Biology, National Institute of Oncology</s1><s2>Budapest</s2><s3>HUN</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gusterson, Barry A" sort="Gusterson, Barry A" uniqKey="Gusterson B" first="Barry A." last="Gusterson">Barry A. Gusterson</name><affiliation><inist:fA14 i1="18"><s1>Department of Pathology, Western Infirmary, University of Glasgow</s1><s2>Scotland</s2><s3>GBR</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pilotti, Silvana" sort="Pilotti, Silvana" uniqKey="Pilotti S" first="Silvana" last="Pilotti">Silvana Pilotti</name><affiliation><inist:fA14 i1="19"><s1>Department of Pathology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Radice, Paolo" sort="Radice, Paolo" uniqKey="Radice P" first="Paolo" last="Radice">Paolo Radice</name><affiliation><inist:fA14 i1="20"><s1>Department of Experimental Oncology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scherneck, Siegfried" sort="Scherneck, Siegfried" uniqKey="Scherneck S" first="Siegfried" last="Scherneck">Siegfried Scherneck</name><affiliation><inist:fA14 i1="21"><s1>Max-Delbruck-Centrum fur Moleculare Medizin, Tumorgenetik</s1><s2>Berlin</s2><s3>DEU</s3><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sobol, Hagay" sort="Sobol, Hagay" uniqKey="Sobol H" first="Hagay" last="Sobol">Hagay Sobol</name><affiliation><inist:fA14 i1="22"><s1>Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute</s1><s2>Marseille</s2><s3>FRA</s3><sZ>30 aut.</sZ><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Jacquemier, Jocelyne" sort="Jacquemier, Jocelyne" uniqKey="Jacquemier J" first="Jocelyne" last="Jacquemier">Jocelyne Jacquemier</name><affiliation><inist:fA14 i1="22"><s1>Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute</s1><s2>Marseille</s2><s3>FRA</s3><sZ>30 aut.</sZ><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wagner, Teresa" sort="Wagner, Teresa" uniqKey="Wagner T" first="Teresa" last="Wagner">Teresa Wagner</name><affiliation><inist:fA14 i1="23"><s1>Department of Obstetrics and Gynaecology, General Hospital, University of Vienna</s1><s3>AUT</s3><sZ>32 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Peto, Julian" sort="Peto, Julian" uniqKey="Peto J" first="Julian" last="Peto">Julian Peto</name><affiliation><inist:fA14 i1="24"><s1>Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories</s1><s3>GBR</s3><sZ>33 aut.</sZ><sZ>34 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="25"><s1>London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stratton, Michael R" sort="Stratton, Michael R" uniqKey="Stratton M" first="Michael R." last="Stratton">Michael R. Stratton</name><affiliation><inist:fA14 i1="24"><s1>Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories</s1><s3>GBR</s3><sZ>33 aut.</sZ><sZ>34 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcguffog, Lesley" sort="Mcguffog, Lesley" uniqKey="Mcguffog L" first="Lesley" last="Mcguffog">Lesley Mcguffog</name></author><author><name sortKey="Easton, Douglas F" sort="Easton, Douglas F" uniqKey="Easton D" first="Douglas F." last="Easton">Douglas F. Easton</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0335175</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0335175 INIST</idno><idno type="RBID">Pascal:05-0335175</idno><idno type="wicri:Area/PascalFrancis/Corpus">004848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype</title><author><name sortKey="Lakhani, Sunil R" sort="Lakhani, Sunil R" uniqKey="Lakhani S" first="Sunil R." last="Lakhani">Sunil R. Lakhani</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Molecular and Cellular Pathology, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Reis Filho, Jorge S" sort="Reis Filho, Jorge S" uniqKey="Reis Filho J" first="Jorge S." last="Reis-Filho">Jorge S. Reis-Filho</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fulford, Laura" sort="Fulford, Laura" uniqKey="Fulford L" first="Laura" last="Fulford">Laura Fulford</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation><inist:fA14 i1="03"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Van Dervijver, Marc" sort="Van Dervijver, Marc" uniqKey="Van Dervijver M" first="Marc" last="Van Dervijver">Marc Van Dervijver</name><affiliation><inist:fA14 i1="04"><s1>The Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Parry, Suzanne" sort="Parry, Suzanne" uniqKey="Parry S" first="Suzanne" last="Parry">Suzanne Parry</name><affiliation><inist:fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bishop, Timothy" sort="Bishop, Timothy" uniqKey="Bishop T" first="Timothy" last="Bishop">Timothy Bishop</name><affiliation><inist:fA14 i1="05"><s1>Imperial Cancer Research Fund Genetic Epidemiology Laboratory, St. James University Hospital</s1><s2>Leeds</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Benitez, Javier" sort="Benitez, Javier" uniqKey="Benitez J" first="Javier" last="Benitez">Javier Benitez</name><affiliation><inist:fA14 i1="06"><s1>Department of Genetics, Dpto Genetica Humana. Centro Nacional nvestigaciones Oncológicas</s1><s2>Madrid</s2><s3>ESP</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rivas, Carmen" sort="Rivas, Carmen" uniqKey="Rivas C" first="Carmen" last="Rivas">Carmen Rivas</name><affiliation><inist:fA14 i1="07"><s1>Department of Pathology, Fundación Jiménez Díaz, Autonomous University of Madrid</s1><s2>Madrid</s2><s3>ESP</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bignon, Yves Jean" sort="Bignon, Yves Jean" uniqKey="Bignon Y" first="Yves-Jean" last="Bignon">Yves-Jean Bignon</name><affiliation><inist:fA14 i1="03"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chang Claude, Jenny" sort="Chang Claude, Jenny" uniqKey="Chang Claude J" first="Jenny" last="Chang-Claude">Jenny Chang-Claude</name><affiliation><inist:fA14 i1="08"><s1>Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hamann, Ute" sort="Hamann, Ute" uniqKey="Hamann U" first="Ute" last="Hamann">Ute Hamann</name><affiliation><inist:fA14 i1="08"><s1>Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cornelisse, Cees J" sort="Cornelisse, Cees J" uniqKey="Cornelisse C" first="Cees J." last="Cornelisse">Cees J. Cornelisse</name><affiliation><inist:fA14 i1="09"><s1>Department of Genetics and Pathology, Leiden University</s1><s2>Leiden</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Devilee, Peter" sort="Devilee, Peter" uniqKey="Devilee P" first="Peter" last="Devilee">Peter Devilee</name><affiliation><inist:fA14 i1="09"><s1>Department of Genetics and Pathology, Leiden University</s1><s2>Leiden</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Beckmann, Matthias W" sort="Beckmann, Matthias W" uniqKey="Beckmann M" first="Matthias W." last="Beckmann">Matthias W. Beckmann</name><affiliation><inist:fA14 i1="10"><s1>Departments of Obstetrics and Gynecology, Friedrich Alexander University</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Nestle Kr Mling, Carolin" sort="Nestle Kr Mling, Carolin" uniqKey="Nestle Kr Mling C" first="Carolin" last="Nestle-Kr Mling">Carolin Nestle-Kr Mling</name><affiliation><inist:fA14 i1="10"><s1>Departments of Obstetrics and Gynecology, Friedrich Alexander University</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Daly, Peter A" sort="Daly, Peter A" uniqKey="Daly P" first="Peter A." last="Daly">Peter A. Daly</name><affiliation><inist:fA14 i1="11"><s1>Department of Medicine, Trinity College Medical School, St James Hospital</s1><s2>Dublin</s2><s3>IRL</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Haites, Neva" sort="Haites, Neva" uniqKey="Haites N" first="Neva" last="Haites">Neva Haites</name><affiliation><inist:fA14 i1="12"><s1>Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen</s1><s2>Aberdeen</s2><s3>GBR</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Varley, Jenny" sort="Varley, Jenny" uniqKey="Varley J" first="Jenny" last="Varley">Jenny Varley</name><affiliation><inist:fA14 i1="13"><s1>CRUK Cancer Genetics Group, Paterson Institute for Cancer Research</s1><s2>Manchester</s2><s3>GBR</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lalloo, Fiona" sort="Lalloo, Fiona" uniqKey="Lalloo F" first="Fiona" last="Lalloo">Fiona Lalloo</name><affiliation><inist:fA14 i1="14"><s1>Department of Medical Genetics, St. Mary's Hospital</s1><s2>Manchester</s2><s3>GBR</s3><sZ>20 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Evans, Gareth" sort="Evans, Gareth" uniqKey="Evans G" first="Gareth" last="Evans">Gareth Evans</name><affiliation><inist:fA14 i1="14"><s1>Department of Medical Genetics, St. Mary's Hospital</s1><s2>Manchester</s2><s3>GBR</s3><sZ>20 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Maugard, Christine" sort="Maugard, Christine" uniqKey="Maugard C" first="Christine" last="Maugard">Christine Maugard</name><affiliation><inist:fA14 i1="15"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Meijers Heijboer, Hanne" sort="Meijers Heijboer, Hanne" uniqKey="Meijers Heijboer H" first="Hanne" last="Meijers-Heijboer">Hanne Meijers-Heijboer</name><affiliation><inist:fA14 i1="16"><s1>Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>23 aut.</sZ><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Klijn, Jan G M" sort="Klijn, Jan G M" uniqKey="Klijn J" first="Jan G. M." last="Klijn">Jan G. M. Klijn</name><affiliation><inist:fA14 i1="16"><s1>Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>23 aut.</sZ><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Olah, Edith" sort="Olah, Edith" uniqKey="Olah E" first="Edith" last="Olah">Edith Olah</name><affiliation><inist:fA14 i1="17"><s1>Department of Molecular Biology, National Institute of Oncology</s1><s2>Budapest</s2><s3>HUN</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gusterson, Barry A" sort="Gusterson, Barry A" uniqKey="Gusterson B" first="Barry A." last="Gusterson">Barry A. Gusterson</name><affiliation><inist:fA14 i1="18"><s1>Department of Pathology, Western Infirmary, University of Glasgow</s1><s2>Scotland</s2><s3>GBR</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pilotti, Silvana" sort="Pilotti, Silvana" uniqKey="Pilotti S" first="Silvana" last="Pilotti">Silvana Pilotti</name><affiliation><inist:fA14 i1="19"><s1>Department of Pathology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Radice, Paolo" sort="Radice, Paolo" uniqKey="Radice P" first="Paolo" last="Radice">Paolo Radice</name><affiliation><inist:fA14 i1="20"><s1>Department of Experimental Oncology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scherneck, Siegfried" sort="Scherneck, Siegfried" uniqKey="Scherneck S" first="Siegfried" last="Scherneck">Siegfried Scherneck</name><affiliation><inist:fA14 i1="21"><s1>Max-Delbruck-Centrum fur Moleculare Medizin, Tumorgenetik</s1><s2>Berlin</s2><s3>DEU</s3><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sobol, Hagay" sort="Sobol, Hagay" uniqKey="Sobol H" first="Hagay" last="Sobol">Hagay Sobol</name><affiliation><inist:fA14 i1="22"><s1>Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute</s1><s2>Marseille</s2><s3>FRA</s3><sZ>30 aut.</sZ><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Jacquemier, Jocelyne" sort="Jacquemier, Jocelyne" uniqKey="Jacquemier J" first="Jocelyne" last="Jacquemier">Jocelyne Jacquemier</name><affiliation><inist:fA14 i1="22"><s1>Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute</s1><s2>Marseille</s2><s3>FRA</s3><sZ>30 aut.</sZ><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wagner, Teresa" sort="Wagner, Teresa" uniqKey="Wagner T" first="Teresa" last="Wagner">Teresa Wagner</name><affiliation><inist:fA14 i1="23"><s1>Department of Obstetrics and Gynaecology, General Hospital, University of Vienna</s1><s3>AUT</s3><sZ>32 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Peto, Julian" sort="Peto, Julian" uniqKey="Peto J" first="Julian" last="Peto">Julian Peto</name><affiliation><inist:fA14 i1="24"><s1>Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories</s1><s3>GBR</s3><sZ>33 aut.</sZ><sZ>34 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="25"><s1>London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>33 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stratton, Michael R" sort="Stratton, Michael R" uniqKey="Stratton M" first="Michael R." last="Stratton">Michael R. Stratton</name><affiliation><inist:fA14 i1="24"><s1>Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories</s1><s3>GBR</s3><sZ>33 aut.</sZ><sZ>34 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcguffog, Lesley" sort="Mcguffog, Lesley" uniqKey="Mcguffog L" first="Lesley" last="Mcguffog">Lesley Mcguffog</name></author><author><name sortKey="Easton, Douglas F" sort="Easton, Douglas F" uniqKey="Easton D" first="Douglas F." last="Easton">Douglas F. Easton</name></author></analytic><series><title level="j" type="main">Clinical cancer research</title><title level="j" type="abbreviated">Clin. cancer res.</title><idno type="ISSN">1078-0432</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical cancer research</title><title level="j" type="abbreviated">Clin. cancer res.</title><idno type="ISSN">1078-0432</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>BRCA1 gene</term><term>Biological receptor</term><term>Breast cancer</term><term>Human</term><term>Malignant tumor</term><term>Mammary gland diseases</term><term>Phenotype</term><term>Prediction</term><term>Predictive factor</term><term>Tumor suppressor gene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Prédiction</term><term>Facteur prédictif</term><term>Gène suppresseur tumeur</term><term>Gène BRCA1</term><term>Homme</term><term>Glande mammaire pathologie</term><term>Tumeur maligne</term><term>Récepteur biologique</term><term>Phénotype</term><term>Cancer sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose:To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus, 12%; CK5/6: 58% versus 7%; CK17: 53%versus10%; osteonectin: 43%versus19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1078-0432</s0></fA01><fA03 i2="1"><s0>Clin. cancer res.</s0></fA03><fA05><s2>11</s2></fA05><fA06><s2>14</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype</s1></fA08><fA11 i1="01" i2="1"><s1>LAKHANI (Sunil R.)</s1></fA11><fA11 i1="02" i2="1"><s1>REIS-FILHO (Jorge S.)</s1></fA11><fA11 i1="03" i2="1"><s1>FULFORD (Laura)</s1></fA11><fA11 i1="04" i2="1"><s1>PENAULT-LLORCA (Frederique)</s1></fA11><fA11 i1="05" i2="1"><s1>VAN DERVIJVER (Marc)</s1></fA11><fA11 i1="06" i2="1"><s1>PARRY (Suzanne)</s1></fA11><fA11 i1="07" i2="1"><s1>BISHOP (Timothy)</s1></fA11><fA11 i1="08" i2="1"><s1>BENITEZ (Javier)</s1></fA11><fA11 i1="09" i2="1"><s1>RIVAS (Carmen)</s1></fA11><fA11 i1="10" i2="1"><s1>BIGNON (Yves-Jean)</s1></fA11><fA11 i1="11" i2="1"><s1>CHANG-CLAUDE (Jenny)</s1></fA11><fA11 i1="12" i2="1"><s1>HAMANN (Ute)</s1></fA11><fA11 i1="13" i2="1"><s1>CORNELISSE (Cees J.)</s1></fA11><fA11 i1="14" i2="1"><s1>DEVILEE (Peter)</s1></fA11><fA11 i1="15" i2="1"><s1>BECKMANN (Matthias W.)</s1></fA11><fA11 i1="16" i2="1"><s1>NESTLE-KRÄMLING (Carolin)</s1></fA11><fA11 i1="17" i2="1"><s1>DALY (Peter A.)</s1></fA11><fA11 i1="18" i2="1"><s1>HAITES (Neva)</s1></fA11><fA11 i1="19" i2="1"><s1>VARLEY (Jenny)</s1></fA11><fA11 i1="20" i2="1"><s1>LALLOO (Fiona)</s1></fA11><fA11 i1="21" i2="1"><s1>EVANS (Gareth)</s1></fA11><fA11 i1="22" i2="1"><s1>MAUGARD (Christine)</s1></fA11><fA11 i1="23" i2="1"><s1>MEIJERS-HEIJBOER (Hanne)</s1></fA11><fA11 i1="24" i2="1"><s1>KLIJN (Jan G. M.)</s1></fA11><fA11 i1="25" i2="1"><s1>OLAH (Edith)</s1></fA11><fA11 i1="26" i2="1"><s1>GUSTERSON (Barry A.)</s1></fA11><fA11 i1="27" i2="1"><s1>PILOTTI (Silvana)</s1></fA11><fA11 i1="28" i2="1"><s1>RADICE (Paolo)</s1></fA11><fA11 i1="29" i2="1"><s1>SCHERNECK (Siegfried)</s1></fA11><fA11 i1="30" i2="1"><s1>SOBOL (Hagay)</s1></fA11><fA11 i1="31" i2="1"><s1>JACQUEMIER (Jocelyne)</s1></fA11><fA11 i1="32" i2="1"><s1>WAGNER (Teresa)</s1></fA11><fA11 i1="33" i2="1"><s1>PETO (Julian)</s1></fA11><fA11 i1="34" i2="1"><s1>STRATTON (Michael R.)</s1></fA11><fA11 i1="35" i2="1"><s1>MCGUFFOG (Lesley)</s1></fA11><fA11 i1="36" i2="1"><s1>EASTON (Douglas F.)</s1></fA11><fA14 i1="01"><s1>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="02"><s1>Molecular and Cellular Pathology, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="04"><s1>The Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Imperial Cancer Research Fund Genetic Epidemiology Laboratory, St. James University Hospital</s1><s2>Leeds</s2><s3>GBR</s3><sZ>7 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Genetics, Dpto Genetica Humana. Centro Nacional nvestigaciones Oncológicas</s1><s2>Madrid</s2><s3>ESP</s3><sZ>8 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Pathology, Fundación Jiménez Díaz, Autonomous University of Madrid</s1><s2>Madrid</s2><s3>ESP</s3><sZ>9 aut.</sZ></fA14><fA14 i1="08"><s1>Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Genetics and Pathology, Leiden University</s1><s2>Leiden</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></fA14><fA14 i1="10"><s1>Departments of Obstetrics and Gynecology, Friedrich Alexander University</s1><s2>Erlangen</s2><s3>DEU</s3><sZ>15 aut.</sZ><sZ>16 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Medicine, Trinity College Medical School, St James Hospital</s1><s2>Dublin</s2><s3>IRL</s3><sZ>17 aut.</sZ></fA14><fA14 i1="12"><s1>Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen</s1><s2>Aberdeen</s2><s3>GBR</s3><sZ>18 aut.</sZ></fA14><fA14 i1="13"><s1>CRUK Cancer Genetics Group, Paterson Institute for Cancer Research</s1><s2>Manchester</s2><s3>GBR</s3><sZ>19 aut.</sZ></fA14><fA14 i1="14"><s1>Department of Medical Genetics, St. Mary's Hospital</s1><s2>Manchester</s2><s3>GBR</s3><sZ>20 aut.</sZ><sZ>21 aut.</sZ></fA14><fA14 i1="15"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>22 aut.</sZ></fA14><fA14 i1="16"><s1>Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>23 aut.</sZ><sZ>24 aut.</sZ></fA14><fA14 i1="17"><s1>Department of Molecular Biology, National Institute of Oncology</s1><s2>Budapest</s2><s3>HUN</s3><sZ>25 aut.</sZ></fA14><fA14 i1="18"><s1>Department of Pathology, Western Infirmary, University of Glasgow</s1><s2>Scotland</s2><s3>GBR</s3><sZ>26 aut.</sZ></fA14><fA14 i1="19"><s1>Department of Pathology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>27 aut.</sZ></fA14><fA14 i1="20"><s1>Department of Experimental Oncology, Istituto Nazionale Tumori</s1><s2>Milan</s2><s3>ITA</s3><sZ>28 aut.</sZ></fA14><fA14 i1="21"><s1>Max-Delbruck-Centrum fur Moleculare Medizin, Tumorgenetik</s1><s2>Berlin</s2><s3>DEU</s3><sZ>29 aut.</sZ></fA14><fA14 i1="22"><s1>Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute</s1><s2>Marseille</s2><s3>FRA</s3><sZ>30 aut.</sZ><sZ>31 aut.</sZ></fA14><fA14 i1="23"><s1>Department of Obstetrics and Gynaecology, General Hospital, University of Vienna</s1><s3>AUT</s3><sZ>32 aut.</sZ></fA14><fA14 i1="24"><s1>Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories</s1><s3>GBR</s3><sZ>33 aut.</sZ><sZ>34 aut.</sZ></fA14><fA14 i1="25"><s1>London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>33 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Breast Cancer Linkage Consortium</s1><s3>INC</s3></fA17><fA20><s1>5175-5180</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26073</s2><s5>354000137962310150</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>28 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0335175</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Clinical cancer research</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Purpose:To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus, 12%; CK5/6: 58% versus 7%; CK17: 53%versus10%; osteonectin: 43%versus19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02R</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Prédiction</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Prediction</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Predicción</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Facteur prédictif</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Predictive factor</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Factor predictivo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Gène suppresseur tumeur</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Tumor suppressor gene</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Gen supresor tumor</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Gène BRCA1</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>BRCA1 gene</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Gen BRCA1</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Mammary gland diseases</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Glándula mamaria patología</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Tumeur maligne</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Malignant tumor</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Tumor maligno</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Récepteur biologique</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Biological receptor</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Receptor biológico</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Phénotype</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Phenotype</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Fenotipo</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancer sein</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Breast cancer</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cáncer del pecho</s0><s4>CD</s4><s5>96</s5></fC03><fN21><s1>234</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 05-0335175 INIST</NO><ET>Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype</ET><AU>LAKHANI (Sunil R.); REIS-FILHO (Jorge S.); FULFORD (Laura); PENAULT-LLORCA (Frederique); VAN DERVIJVER (Marc); PARRY (Suzanne); BISHOP (Timothy); BENITEZ (Javier); RIVAS (Carmen); BIGNON (Yves-Jean); CHANG-CLAUDE (Jenny); HAMANN (Ute); CORNELISSE (Cees J.); DEVILEE (Peter); BECKMANN (Matthias W.); NESTLE-KRÄMLING (Carolin); DALY (Peter A.); HAITES (Neva); VARLEY (Jenny); LALLOO (Fiona); EVANS (Gareth); MAUGARD (Christine); MEIJERS-HEIJBOER (Hanne); KLIJN (Jan G. M.); OLAH (Edith); GUSTERSON (Barry A.); PILOTTI (Silvana); RADICE (Paolo); SCHERNECK (Siegfried); SOBOL (Hagay); JACQUEMIER (Jocelyne); WAGNER (Teresa); PETO (Julian); STRATTON (Michael R.); MCGUFFOG (Lesley); EASTON (Douglas F.)</AU><AF>The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 6 aut.); Molecular and Cellular Pathology, University of Queensland/Brisbane/Australie (1 aut.); Centre Jean Perrin/Clermont-Ferrand/France (4 aut., 10 aut.); The Netherlands Cancer Institute/Amsterdam/Pays-Bas (5 aut.); Imperial Cancer Research Fund Genetic Epidemiology Laboratory, St. James University Hospital/Leeds/Royaume-Uni (7 aut.); Department of Genetics, Dpto Genetica Humana. Centro Nacional nvestigaciones Oncológicas/Madrid/Espagne (8 aut.); Department of Pathology, Fundación Jiménez Díaz, Autonomous University of Madrid/Madrid/Espagne (9 aut.); Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis/Heidelberg/Allemagne (11 aut., 12 aut.); Department of Genetics and Pathology, Leiden University/Leiden/Pays-Bas (13 aut., 14 aut.); Departments of Obstetrics and Gynecology, Friedrich Alexander University/Erlangen/Allemagne (15 aut., 16 aut.); Department of Medicine, Trinity College Medical School, St James Hospital/Dublin/Irlande (17 aut.); Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen/Aberdeen/Royaume-Uni (18 aut.); CRUK Cancer Genetics Group, Paterson Institute for Cancer Research/Manchester/Royaume-Uni (19 aut.); Department of Medical Genetics, St. Mary's Hospital/Manchester/Royaume-Uni (20 aut., 21 aut.); University Hospital/Nantes/France (22 aut.); Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam/Rotterdam/Pays-Bas (23 aut., 24 aut.); Department of Molecular Biology, National Institute of Oncology/Budapest/Hongrie (25 aut.); Department of Pathology, Western Infirmary, University of Glasgow/Scotland/Royaume-Uni (26 aut.); Department of Pathology, Istituto Nazionale Tumori/Milan/Italie (27 aut.); Department of Experimental Oncology, Istituto Nazionale Tumori/Milan/Italie (28 aut.); Max-Delbruck-Centrum fur Moleculare Medizin, Tumorgenetik/Berlin/Allemagne (29 aut.); Department of Genetic Oncology and Cancer Control, Institut National de la Sante et de la Recherche Medicale EPI 9939, Paoli Calmettes Institute/Marseille/France (30 aut., 31 aut.); Department of Obstetrics and Gynaecology, General Hospital, University of Vienna/Autriche (32 aut.); Sections of Cancer Genetics and Epidemiology, Institute of Cancer Research, Haddow Laboratories/Royaume-Uni (33 aut., 34 aut.); London School of Hygiene and Tropical Medicine/London/Royaume-Uni (33 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Clinical cancer research; ISSN 1078-0432; Etats-Unis; Da. 2005; Vol. 11; No. 14; Pp. 5175-5180; Bibl. 28 ref.</SO><LA>Anglais</LA><EA>Purpose:To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus, 12%; CK5/6: 58% versus 7%; CK17: 53%versus10%; osteonectin: 43%versus19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.</EA><CC>002B02R</CC><FD>Prédiction; Facteur prédictif; Gène suppresseur tumeur; Gène BRCA1; Homme; Glande mammaire pathologie; Tumeur maligne; Récepteur biologique; Phénotype; Cancer sein</FD><ED>Prediction; Predictive factor; Tumor suppressor gene; BRCA1 gene; Human; Mammary gland diseases; Malignant tumor; Biological receptor; Phenotype; Breast cancer</ED><SD>Predicción; Factor predictivo; Gen supresor tumor; Gen BRCA1; Hombre; Glándula mamaria patología; Tumor maligno; Receptor biológico; Fenotipo; Cáncer del pecho</SD><LO>INIST-26073.354000137962310150</LO><ID>05-0335175</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 004848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:05-0335175
|texte= Prediction of BRCA1 status in patients with breast cancer using estroqen receptor and basal phenotype
}}
| This area was generated with Dilib version V0.6.33. |  |